eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 69
Original paper

Molecular prognostic factors in early-stage cervical adenocarcinoma

Maciej Bodzek, Paweł Blecharz, Janusz Ryś, Wiktor Szatkowski, Marek Jasiówka, Paweł Majchrzak, Krzysztof Halaszka, Anna Kruczak, Bożena Lackowska

Pol J Pathol 2018; 69 (3): 285-291
Online publish date: 2018/11/20
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Within the past years the proportion of cervical adenocarcinomas has increased, however, there is a shortage of data regarding immunohistochemical and molecular features and their prognostic relevance in early-stage cervical adenocarcinoma (esCAC). Aim of the present study was to evaluate molecular prognostic factors in esCAC patients treated with primary surgery.

Analyses of surgical specimens in 59 patients with esCAC were performed on fixed paraffin-embedded sections of tumour tissue. Tumour tissue sections were routinely stained with hematoxylin and eosin followed by microscopic examination. Immunohistochemical analyses (IHC) were performed on paraffin-embedded section. Flow cytometry (FCM) analysis of paraffin-embedded tumor tissue was performed using flow cytometer FACSCalibur equipped with argon laser. DNA histogram analysis was performed with ModFit application. Treatment effectiveness was evaluated using overall 5-year survival. Survival probability was estimated using the Kaplan-Meier method.

Overall survival rate estimated using Kaplan-Meier method was 74.6%. Among the IHC and FCM features univariate analysis showed statistical significance of nm23-H1 gene expression and total S-phase fraction ≤ 11.9% (S-TOT). In multi-

variate analysis LVSI and parametrial involvement had significant, negative impact on survival (HR = 8.04, p < 0.003 and HR = 4.03, p < 0.017, respectively). However, none of the tested IHC and FCM features had any influence on overall 5-year survival.

cervical adenocarcinoma, flow cytometry, prognosis

Wright C, Ferenczy A, Kurman RJ. Carcinoma and Rother tumors of the cervix. In: Kurman RJ (ed.). Blaustein’s Pathology of the Female Genital tract, 4th ed. New York, Springer-Verlag, 1994; 279-326.
Sherman ME, Wang SS, Carreon J, et al. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer 2005; 103: 1258-1264.
Smith HO, Tiffany M, Qualls CR, et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the U.S.: A 24-year population-based study. Gynecol Oncol 2000; 78: 97-105.
Peters RK, Chao A, Mack TM, et al. Increased frequency of adenocarcinoma of the uterine cervix in young women in Los Angeles County. J Natl Cancer Inst 1986; 76: 423-428.
Schwartz SM, Weiss N. Increased incidence of adenocarcinoma of the cervix in young women in the United States. Am J Epidemiol 1986; 124: 1045-1047.
Anton-Culver H, Bloss JD, Bringman D, et al. Comparison of adenocarcinoma and squamous cell carcinoma of the uterine cervix: A population based epidemiologic study. Am J Obstet Gynecol 1992; 186: 1507-1514.
Hopkins P, Morley GW. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 1991; 7: 912-917.
Nieminen P, Kallio M, Hakama M. The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri. Obstet Gynecol 1995; 85: 1017-1021.
Platz CE, Benda JA. Histology of cancer, incidence and prognosis: SEER population-based data, 1973-1987, female genital tract cancer. Cancer 1995; 75: 270-294.
Iversen T, Abeler V, Kjrostad KE. Factors influencing the treatment of patients with stage IA carcinoma of the cervix. Br J Obstet Gynaecol 1979; 86: 593-597.
Qizilbash AH. In situ and microinvasive adenocarcinoma of the uterine cervix: A clinical, cytologic and histologic study of 14 cases. Am I Clin Pathol 1975; 64: 155-170.
Schorge JO, Lee KR, Flynn CE, et al. Stage 1A1 cervical adenocarcinoma: Definition and treatment. Obstet Gynecol 1999; 93: 219-222.
Kaku T, Kamura T, Sakai K, et al. Early adenocarcinoma of the uterine cervix. Gynecol Oncol 1997; 65: 281-285.
Hopkins P, Peters WA, Anderson W, et al. Invasive cervical cancer treated initially by standard hysterectomy. Gynecol Oncol 1990; 36: 7-12.
McHale M, Le TD, Burger RA, et al. Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix. Obstet Gynecol 2001; 98: 726-731.
Matsukuma K, Tsukamoto N, Kaku T, et al. Early adenocarcinoma of the uterine cervix: its histologic and immunohistologic study. Gynecol Oncol 1989; 35: 38-43.
Rollason TP, Cullimore J, Bradgate MG. A suggested columnar cell morphological equivalent of squamous carcinoma in situ with early stromal invasion. Int J Gynaecol Pathol 1989; 8: 230-236.
Kaspar HG, Dinh TV, Doherty MG, et al. Clinical implications of tumor volume measurement in stage I adenocarcinoma of the cervix. Obstet Gynecol 1993; 81: 296-300.
Kurman RJ, Carcangiu ML, Herrington CS, et al. (eds.). WHO Classification of Tumours of Female Reproductive Organs. IARC, Lyon 2014.
Shankey TW, Rabinovitch PS, Bagwell B, et al. Guidelines for implementation of clinical DNA cytometry. Cytometry 1993; 14: 472-477.
Hedley DW, Friedlander ML, Taylor IW, et al. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31: 1333-1335.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34: 585-612.
Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B 1972; 34: 187.
Mandai M, Konishi I, Komatsu T, et al. Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression. Br J Cancer 1995; 72: 691-695.
Huang Y, Cai S, Yu S. Relationship between nm23-H1 expression and lymph node metastasis and prognosis in cervical cancer. Zhonghua Fu Chan Ke Za Zhi 1997; 32: 718-721.
Kristensen GB, Holm R, Abeler VM, et al. Evaluation of the prognostic significance of nm23/NDP kinase protein expression in cervical carcinoma: an immunohistochemical study. Gynecol Oncol 1996; 61: 378-383.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe